{"id":"W3024966661","doi":"10.1016/j.clgc.2020.05.006","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; Bristol-Myers Squibb Canada; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Daiichi-Sankyo; Pfizer; Moderna; Five Prime Therapeutics; Mirati Therapeutics; Clovis Oncology; Roche; Karyopharm Therapeutics; Novartis; AbbVie; Sanofi; MedImmune; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Chromophobe cell; Nivolumab; Internal medicine; Renal cell carcinoma; Adverse effect; Regimen; Gastroenterology; Clinical endpoint; Phases of clinical research; Rash; Clear cell; Urology; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001727219,0.0003536368,0.0007053884,0.0001544206,0.0002201747,0.0005870484,0.0004311381,0.0004478015,0.00157779],"category_scores_gemma":[0.001030412,0.0001425705,0.0007251709,0.0001847493,0.0002981858,0.0002700797,0.0002032457,0.0007223255,0.000302741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001331733,"about_ca_system_score_gemma":0.001503405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00228205,"about_ca_topic_score_gemma":0.004843086,"domain_scores_codex":[0.9996008,0.0001834356,0.00002754457,0.00005986195,0.00008328766,0.00004505373],"domain_scores_gemma":[0.9992074,0.0001641093,0.0002002454,0.00007063055,0.0001177861,0.0002397957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4291653,0.01369995,0.2277595,0.002318104,0.0056009,0.0003930271,0.0004398522,0.00510671,0.06775042,0.0004366091,0.01464927,0.2326803],"study_design_scores_gemma":[0.2103009,0.238566,0.4953885,0.000289248,0.003982978,0.00113255,0.000191178,0.005768894,0.01868092,0.000513533,0.02506704,0.0001183494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942113,0.00298781,0.0001591968,0.0001497156,0.0000276552,0.0003015178,0.0009850917,0.00002649754,0.001151282],"genre_scores_gemma":[0.9946657,0.0008614301,0.000380379,0.0003828779,0.00003808387,0.0002011392,0.002789768,0.00001097461,0.0006696152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00228205,"threshold_uncertainty_score":0.009662449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03434760163426389,"score_gpt":0.3187661217690864,"score_spread":0.2844185201348225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}